Dr. Canfield named urology chief at UTHealth
Urologic oncologist Steven E. Canfield, MD, has been named chief of the division of urology in the department of surgery at The University of Texas Health Science Center at Houston (UTHealth) Medical School.
Urologic oncologist Steven E. Canfield, MD, has been named chief of the division of urology in the department of surgery at The University of Texas Health Science Center at Houston (UTHealth) Medical School.
"Dr. Canfield has served as the program director of the division of urology for the last few years, and it has been a pleasure to work him," said Richard J. Andrassy, MD, professor and chairman of the UTHealth Surgery Department. "We are pleased he has accepted the position of chief of urology."
Dr. Canfield, an associate professor of surgery at UTHealth, specializes in the treatment of prostate, bladder, and kidney cancer. He graduated from Thomas Jefferson University’s Jefferson Medical College in Philadelphia and completed an internship and residency at the Mount Sinai School of Medicine in New York. Later, he finished a 3-year fellowship at the University of Texas MD Anderson Cancer Center, Houston.
Dr. Canfield is the chief of urology at Lyndon B. Johnson General Hospital, Houston, in partnership with the Harris County Hospital District and the MD Anderson Cancer Center. He is an investigator in ongoing clinical trials and has published more than 70 manuscripts, chapters, and editorial reviews.
Dr. Canfield succeeds Dr. Andrassy, who served as interim chief, and O. Lenaine Westney, MD, who left the position in January 2010 and is currently associate professor of urology at the University of Texas MD Anderson Cancer Center, Houston.
Go back to this issue of Urology Times eNews.
Related Content
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.
